| Cat.No. | Name | Information |
|---|---|---|
| M1959 | Oseltamivir | Oseltamivir is a potent and selective inhibitor of influenza virus neuraminidase enzyme. |
| M5055 | Peramivir | Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M5083 | β-Cyclodextrin | β-Cyclodextrin affects the formation of isomerization products during peptide deamidation. |
| M1707 | Entecavir Monohydrate | Entecavir Hydrate is a class of antiviral compounds. |
| M3357 | Telbivudine | Telbivudine is an antiviral compound used in hepatitis B research. |
| M1695 | Cidofovir | Cidofovir (Vistide) is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis. |
| M4718 | Dendrobine | Dendrobine is an alkaloid isolated from Dendrobium nobile. Dendrobine has antiviral activity against influenza A virus, IC50 values for A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1) and A/Aichi/2/68 (H3N2) were 3.39 μM, 2.16 μM and 5.32 μM, respectively. |
| M10421 | Sodium citrate (dihydrate) | Sodium citrate dehydrate is an anticoagulant and also used as a buffer and food preservatives. |
| M3222 | Peramivir Trihydrate | Peramivir Trihydrate is a trihydrate of the anti-infection agent peramivir (RWJ-270201,BCX-1812) which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M4789 | Isoscopoletin | Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active ingredient in artemisia argyi leaves. Isoscopoletin showed significant inhibition of cell proliferation, with IC50 values of 4.0 μM and 1.6 μM against human CCRF-CEM leukemia cells and CEM/ADR5000 drug-resistant subline, respectively. Isoscopoletin (6-Hydroxy-7-methoxycoumarin) has the activity of inhibiting HBV replication. |
| M25297 | Rafivirumab | Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails. |
| M25266 | Panobacumab | Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa. |
| M25238 | Pagibaximab | Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis. |
| M25237 | Exbivirumab | Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). |
| M25236 | Libivirumab | Libivirumab (17.1.41) is a humanized anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively. |
| M25197 | Ogalvibart | Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model. |
| M25189 | Lomtegovimab | Lomtegovimab (BI 767551) is a humanized anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19. |
| M25188 | Rimteravimab | Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2. |
| M25186 | Adintrevimab | Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential. |
| M25184 | Romlusevimab | Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). |
| M25183 | Amubarvimab | Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants. |
| M25174 | Fiztasovimab | Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV. |
| M25166 | Regdanvimab | Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19. |
| M25154 | Quisovalimab | Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies. |
| M25153 | Etesevimab | Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody. |
| M25152 | Bamlanivimab | Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and Drug Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab. |
| M25151 | Beludavimab | Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM. |
| M25150 | Sotrovimab | Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease. |
| M25149 | Tixagevimab | Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor. |
| M25148 | Cilgavimab | Cilgavimab (AZD-1061; COV2-2130) is a humanized SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab . Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
